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Abstract Previous studies have shown that Disabled-2 (DAB2)
is up-regulated during megakaryocytic di¡erentiation of human
K562 cells. To delineate the consequences of DAB2 induction, a
DNA vector-based small interfering RNA (siRNA) was de-
signed to intervene in DAB2 expression. We found that DAB2
siRNA speci¢cally inhibited DAB2 induction, resulting in the
modulation of cell^cell adhesion and mitogen-activated protein
kinase (MAPK) phosphorylation. The morphological changes
and L3 integrin expression associated with megakaryocytic dif-
ferentiation were not a¡ected. Since the MAPK pathway has
been shown to involve DAB2 induction [Tseng et al., Biochem.
Biophys. Res. Commun. 285 (2001) 129^135], our results sug-
gest a reciprocal regulation between DAB2 and MAPK in the
di¡erentiation of K562 cells. In addition, we have demonstrated
for the ¢rst time that DAB2 siRNA is a valuable tool for un-
veiling the biological consequences of DAB2 expression.
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Disabled-2 (DAB2) is a cytoplasmic adapter protein medi-
ating epidermal growth factor, colony stimulating factor-1,
and transforming growth factor-L cellular signals [1^4]. Like
other adapter proteins, DAB2 has no catalytic activity but
elicits its function through interaction and modulation of oth-
er cellular proteins. Mediated by the N-terminal phosphotyr-
osine interacting domain, DAB2 interacts with the RAS
GTPase-activating protein DIP1/2 as well as the SMAD fam-
ily of transcription factors. These interactions have signi¢cant
functional impact on gene transcription [3,5]. Through the C-
terminus proline-rich sequences, DAB2 interacts with myosin
VI and the adapter protein GRB2 resulting in the modulation
of cellular activity [6^8]. The function of DAB2 is also regu-
lated by both the p42/p44 mitogen-activated protein kinase
(MAPK) pathway and protein kinase C-mediated protein
phosphorylation [8,9]. For instance, phosphorylation of
DAB2 at serine 24 in the N-terminus of DAB2 was shown
to be the key amino acid residue in modulating AP-1 tran-
scriptional activity [8]. These studies suggest that DAB2 in-
volves multiple signaling pathways and modulates cellular
functions through several distinct mechanisms.
The level of DAB2 has signi¢cant impact on cancer devel-
opment and hematopoietic cell di¡erentiation. Aberration of
DAB2 expression has been shown to associate with breast,
prostate, and mouse mammary tumors. Expression of DAB2
in cancer cell lines resulted in cell cycle arrest and a decreased
rate of cell growth [10,11]. On the other hand, during mega-
karyocytic di¡erentiation of the human chronic myeloid leu-
kemic cell line K562, DAB2 is up-regulated in a p42/p44
MAPK-dependent manner [9]. The signi¢cance of DAB2 in-
duction in hematopoietic cell di¡erentiation and signaling has
not yet been addressed. This is partly due to the lack of simple
and valuable genetic tools to disrupt DAB2 expression for
analyzing cellular function.
Recent studies have revealed that RNA interference
(RNAi), a process of homology-dependent degradation of
cognate mRNA by double-stranded RNA (dsRNA), is a
powerful tool in the down-regulation of gene expression
[12]. This phenomenon is commonly present in nematodes,
plants and fungi. In mammalian cells, it was recently shown
that introduction of a small interfering RNA (siRNA), gen-
erally 21^23 nt, could achieve a similar gene inhibitory e¡ect
without the non-speci¢c activation of dsRNA-activated pro-
tein kinase R [13]. In this study, a DNA vector-based DAB2
siRNA is designed and generated for the ¢rst time that
speci¢cally inhibits DAB2 expression. Utilizing the DAB2
siRNA, we demonstrate a role of DAB2 in the control of
cellular adhesive function. The present study also reveals a re-
ciprocal regulation between DAB2 and MAPK during mega-
karyocytic di¡erentiation of K562 cells.
2. Materials and methods
2.1. Materials
K562, HL-60, and MEG-01 cells were from the American Type
Culture Collection (Manassas, VA, USA). HEL cells were a kind
gift from Dr. H. Wu (Department of Pharmacy, Chia Nan University
of Pharmacy and Science, Tainan, Taiwan). p42/p44 MAPK and
phospho-p42/p44 MAPK antibodies were from New England Bio-
Labs (Beverly, MA, USA). The DAB2 antibody p96 was from Trans-
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duction Laboratories (Lexington, KY, USA). The L3 antibody was
from Santa Cruz Biotechnologies (Santa Cruz, CA, USA). 12-O-Tet-
radecanoylphorbol 13-acetate (TPA) and other molecular biology
grade chemicals were from Sigma (St. Louis, MO, USA). The scram-
blase expression plasmid pCI-neo-His9 has been described previously
[14]. pEGFP-C3 and pDsRed1-N1 were from Clontech (Palo Alto,
CA, USA). The DMRIE-C and Lipofectamine 2000 (LF2000) trans-
fection reagents were from Invitrogen (Carlsbad, CA, USA). FITC-
labeled phosphorothioate oligonucleotides (S-oligos) were from Gen-
asia (Taipei, Taiwan). Peptide nucleic acids (PNA) were from Applied
Biosystems (Foster City, CA, USA).
2.2. Plasmid construction
For pCI-neo-hDAB2, human DAB2 cDNA was ampli¢ed by poly-
merase chain reaction (PCR) and then subcloned into the XhoI site of
pCI-neo (Promega). For pTOPO-U6, the RNAi expression cassette
containing the mouse U6 promoter and the termination signal of
RNA polymerase III was inserted into the pCRII-TOPO vector (In-
vitrogen) with the following procedures. First, the mouse U6 pro-
moter (3315 to +1) was PCR-ampli¢ed with the primer set U6-sense
(5P-AGATCTATCCGACGCCGCCATCTCTA-3P) and U6-antisense
(5P-GGATTGGTCTTCGATATCCAAACAAGGCTTTTCTCCAA-
3P) using genomic DNA from mouse 3T3-L1 cells as the template. The
PCR product was subcloned into the pCRII-TOPO vector by the
TOPO cloning technique. Due to the enclosure of the recognition
sequences for BbsI and EcoRV in the U6-antisense PCR primer, these
sites were created at the 3P-end of the promoter and the 5P-end of the
NotI recognition sequence located at the multiple cloning sites. For
inserting the -TTTTT termination sequences of RNA polymerase III,
we annealed the complementary oligonucleotides TS (5P-ATCC-
TTTTTTCACGTAGTGGC-3P) and TAS (5P-GGCCGCCACTACG-
TGAAAAAA-3P). The annealing reaction generated TS/TAS dsDNA
with overhang sequences for BbsI and NotI sites that was ready for
ligating to the BbsI- and NotI-digested pCRII-TOPO plasmid with the
U6 promoter. These steps resulted in the RNAi expression vector
pTOPO-U6 that had the EcoRV and BbsI sites for insertion of
RNAi sequences. In addition, BglII and DraIII cloning sites were
designed for release of the complete RNAi expression cassette and
for the insertion into other expression vectors. For the plasmids
Dab2^419 and Dab2^2112, the complementary oligonucleotides
Dab2^419S (5P-CTGGGTAACATTTCCCTCAAGCTTCAGGGAA-
ATGTTGACCCAG-3P) and Dab2^419AS (5P-GGATCTGGGTA-
ACATTTCCCTGAAGCTTGAGGGAAATGTTGACCCAG-3P), as
well as Dab2^2112S (5P-TTCCAACTGCGGCAGCCACAAGCTT-
CTGGCTGCCGCAGTTGGAA-3P) and Dab2^2112AS (5P-GGA-
TTTCCAACTGCGGCAGCCAGAAGCTTGTGGCTGCCGCAGT-
TGGA-A-3P) were annealed, respectively. The annealing of Dab2^
2112S/Dab2^2112AS or Dab2^419S/Dab2^419AS generated sites cor-
responding to the blunt end and the overhang that matched the
EcoRV- and BbsI-digested pTOPO-U6. The ligation between the an-
nealed oligonucleotides and pTOPO-U6 at the EcoRV and BbsI clon-
ing sites generated Dab2^2112 and Dab2^419, respectively. For
pEGFPC3-DAB2, the human DAB2 cDNA from pCI-neo-hDAB2
was inserted into the XhoI-BamHI site of pEGFP-C3.
2.3. S-oligos and PNA transfection
For transfection of S-oligos, K562 cells were incubated with 4 WM
FITC-labeled S-hDAB2 (5P-AsTGsTCsTAsACsGAsAGsTAsGA-
sAAsC-3P) or AS-hDAB2 (5P-GsTTsTCsTAsCTsTCsGTsTAsGAs-
CAsT-3P) in the presence of DMRIE-C for 7 h. The uptake e⁄ciency
of the S-oligos was monitored by £uorescence microscopy. For PNA
transfection, K562 cells were transfected with 10 WM PNA1 (5P-
CTACTTCGTTAGACATG-Lys-Lys-Lys-3P) and 10 WM PNA2
(5P-AGCATGACTTCCCCGC-Lys-Lys-Lys-3P) in the presence of
LF2000 for 24 h. Cells were harvested for Western blot analysis after
indicated treatments.
2.4. Transient transfection, preparation of cell extracts, and Western
blot analysis
K562 and its subline D-1-4 that barely expressed DAB2 (C.H. Lee
and C.P. Tseng, unpublished data) were cultured as described previ-
ously [9]. For transfection, K562 cells were plated at a density of
2U106/35 mm plate and were applied with 6 Wg DNA premixed
with 10 Wl LF2000. Twenty-four hours later, the transfected cells
were split and cultured at a density of 1.5U104/ml followed by the
indicated treatments. The preparation of cell extracts and Western
blot analysis were performed as described previously [9].
2.5. Cell aggregation and cell adhesion assay
The transfected cells were adjusted to a density of 3U104/ml. Fol-
lowing the indicated treatment for 24 and 48 h, cell clusters with s 5
cells/aggregate were counted under phase contrast microscopy at a
40U magni¢cation power. For quanti¢cation of cell aggregation,
the total numbers of cell clusters in 10 randomly selected ¢elds were
determined. For quanti¢cation of cell adhesion, the cells spreading on
the culture dish were counted under phase contrast microscopy at a
100U magni¢cation power. The total numbers of spreading cells in 10
randomly selected ¢elds were used as the index for cell adhesion.
3. Results
3.1. Design and characterization of DAB2 siRNA
The RNAi technique was recently adapted for modulation
of gene expression in mammalian cells. We generated the
DNA vector-based siRNAs Dab2^419 and Dab2^2112 and
evaluated whether they are the e¡ective DAB2 modulators
(Fig. 1A,B). Sequence analysis revealed that Dab2^419 has
a point deletion that resulted in a mismatch in the dsRNA
region. To determine the inhibitory e¡ect and speci¢city of
DAB2 siRNAs, either Dab2^419 or Dab2^2112 was co-trans-
fected with DAB2 and T7-Tag scramblase expression plas-
mids into D-1-4 cells with a ratio of 5:1:1, 10:1:1 and
25:1:1, respectively. Western blot analysis revealed that
Dab2^2112 but not Dab2^419 inhibited DAB2 expression
(Fig. 1C). Besides, both Dab2^419 and Dab2^2112 had no
e¡ect on the expression of T7-Tag scramblase of which the
mRNA does not contain the target sequences of Dab2 si-
RNA.
The speci¢city of Dab2^2112 was further evaluated using
the enhanced green £uorescent protein (EGFP) expression
system. In our preliminary study, we found that Dab2^2112
did not inhibit EGFP expression (data not shown). We thus
determined whether the fusion of DAB2 cDNA to the EGFP
coding sequences switches EGFP to become a target of Dab2^
2112. The pEGFPC3-DAB2 encoding EGFP-DAB2 fusion
protein was co-transfected with pDsRed1-N1 into K562 cells
in the presence of Dab2^2112 (Fig. 1D). The £uorescent in-
tensity was observed with £uorescence microscopy 48 h after
transfection. We found that the red £uorescent protein (RFP)
encoded by pDsRed1-N1 is expressed at a comparable level in
cells transfected with Dab2^2112 and vector control, indicat-
ing a similar e⁄ciency of the transfections. The results also
suggest that Dab2^2112 did not interfere with RFP expres-
sion. On the other hand, the £uorescent intensity of EGFP-
DAB2 was signi¢cantly reduced in cells expressing Dab2^
2112. Therefore, our results suggest that Dab2^2112 speci¢-
cally modulates DAB2 expression.
3.2. DAB2 siRNA inhibits TPA-induced DAB2 expression in
myeloid leukemic cells
Since DAB2 is expressed at various levels in di¡erent cell
types, the expression patterns of DAB2 in several myeloid
leukemic cells, including K562, MEG-01, HL-60, and HEL
cells, were determined (Fig. 2A). At the exponential growth
phase, K562 and MEG-01 cells had a low level of DAB2,
while HEL cells showed intermediate DAB2 expression. HL-
60 cells had no detectable DAB2. Upon TPA-mediated mega-
karyocytic di¡erentiation of K562, MEG-01, and HEL cells,
DAB2 induction was associated with the di¡erentiation pro-
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cess (Fig. 2A). To unveil the consequences of DAB2 induc-
tion, several approaches were compared for the inhibition of
DAB2 expression. First, FITC-labeled antisense S-oligos tar-
geting the DAB2 translation initiation site were synthesized
and transfected into K562 cells. Although more than 90% of
the cells emitted a £uorescent signal that indicated good trans-
fection e⁄ciency (data not shown), the levels of TPA-induced
DAB2 did not change (Fig. 2B, upper panel). Similarly, in-
troducing DAB2 antisense PNA targeting both the 5P-un-
translated region and the translation initiation site into
K562 cells elicited no change of TPA-induced DAB2 expres-
sion (Fig. 2B, lower panel). To explore the use of DAB2
siRNA to modulate DAB2 induction, either Dab2^419 or
Dab2^2112 was transfected into K562 cells followed by
TPA treatment for 24 and 48 h (Fig. 2C). With a transfection
e⁄ciency of approximately 50%, Dab2^419 had a minimal
e¡ect in the suppression of DAB2 induction. In contrast,
Dab2^2112 decreased the level of TPA-induced DAB2, con-
sistent with its e¡ect on the down-regulation of exogenous
DAB2 expression (Fig. 1). These results suggest that DAB2^
2112, but not the antisense S-oligos and PNA, is a powerful
tool for modulating TPA-induced DAB2 gene expression.
3.3. Dab2^2112 modulates cellular adhesive properties of K562
cells
K562 cells grew in suspension culture as free-£oating cells
and formed cell aggregates within 24^48 h after TPA treat-
ment (Fig. 3A). When observed under light microscopy after
cytospin and Liu’s stain, the TPA-treated cells exhibited typ-
ical megakaryocytic di¡erentiation phenotypes with enlarge-
ment of the majority of cells, a decrease of the N/C ratio, and
the presence of multiple lobes of nuclei (Fig. 3B). To delineate
whether or not DAB2 induction associated with these pheno-
typic changes, we transfected Dab2^2112 into K562 cells fol-
lowed by TPA treatment. We found that, in the Dab2^2112
expressing cells, the number of large cell aggregates (s 5 cells/
aggregate) decreased to approximately 46% of the vector-
transfected control cells 48 h after TPA treatment. Concom-
itant with the decrease of cell aggregation, the adhesion and
spreading of cells to tissue culture dishes increased for approx-
imately 85% (Fig. 3A). In contrast, Dab2^2112 had no e¡ect
on the morphological changes and the up-regulation of integ-
rin L3 associated with megakaryocytic di¡erentiation (Fig.
3B). The e¡ect of Dab2^2112 on K562 cell aggregations could
not be analyzed in HEL and MEG-01 cells since both cell
Fig. 1. Design and characterization of DAB2 siRNA. A: Schematic representation of DAB2 siRNA expression plasmid. The plasmid was de-
signed and constructed as described in Section 2. B: Proposed DAB2 siRNA structures. The putative structures of the dsRNAs formed by
Dab2^2112 and Dab2^419 were shown. C: Speci¢c inhibition of DAB2 expression by DAB2 siRNA. D-1-4 cells were transfected for 48 h with
pTOPO-U6 (lanes 1, 4, 7), Dab2^419 (lanes 2, 5, 8), or Dab2^2112 (lanes 3, 6, 9), as well as DAB2 and T7-Tag scramblase expression plasmids
in ratios of 5:1:1 (lanes 1^3), 10:1:1 (lanes 4^6), and 25:1:1 (lanes 7^9), respectively. pCI-neo was used to bring up the total plasmid DNA to
7 Wg. The total cell lysates were collected and subjected to Western blot analysis with p96 (DAB2), T7-Tag, and L-actin antibodies. D: Either
pTOPO-U6 (upper panel) or Dab2^2112 (lower panel) was cotransfected with pEGFPC3-DAB2 and pDsRed1-N1 into K562 cells in a ratio of
5:1:1 for 48 h. Following transfection, the £uorescent intensity was observed by £uorescence microscopy.
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types did not form cell clusters but attached to the tissue
culture dish [15,16] shortly after TPA treatment (data not
shown). These results suggest that DAB2 induction plays a
role in the control of K562 cell^cell adhesion but is not in-
volved in the megakaryocytic di¡erentiation signals regarding
morphological changes and L3 gene expression.
3.4. Dab2^2112 sustains p42/p44 MAPK phosphorylation/
activation
Induction of DAB2 occurred in a time- and p42/p44
MAPK-dependent manner [9]. In this study, Western blot
analysis with the anti-p96 antibody revealed maximum induc-
tion of DAB2 at 24^48 h after TPA treatment (Fig. 4A).
Concurrently, the sustained activation of MAPK as detected
by anti-phospho-p42/p44 MAPK antibody was drastically re-
duced. The temporal pattern of DAB2 expression and MAPK
phosphorylation suggests a connection between DAB2 and
MAPK in TPA signaling. This hypothesis was characterized
further using the DAB2 siRNA. In this content, Dab2^2112
was transfected into K562 cells to suppress TPA-mediated
DAB2 induction. Following TPA treatment for the indicated
time, the phospho-speci¢c p42/p44 MAPK antibody was used
to analyze the level of MAPK activity. Of the cells expressing
Dab2^2112, p42/p44 MAPK was still activated within 30 min
after TPA treatment (data not shown). The data indicate that
Dab2^2112 does not a¡ect TPA-mediated p42/p44 MAPK
activation. Instead, the Dab2^2112-transfected cells were
found to have a higher level of p42/p44-MAPK phosphoryla-
tion (Fig. 4B). For instance, at 48 h after TPA treatment,
Dab2^2112 reduced the magnitude of MAPK dephosphoryla-
tion and sustained MAPK activity to the level at 12^24 h of
the control cells. These results suggest a role of DAB2 in-
duction in the suppression of MAPK phosphorylation. To
further evaluate this observation, we expressed pCI-neo-
hDAB2 in K562 cells and analyzed the degree of MAPK
phosphorylation. Consistent with the results of Dab2^2112,
the phosphorylation of MAPK was diminished by DAB2 ex-
pression (Fig. 4C). Therefore, up-regulation of DAB2 plays a
role in the decrease of MAPK activity after sustained TPA
treatment.
4. Discussion
The lack of a simple genetic tool to inhibit DAB2 expres-
sion has complicated the investigation of DAB2 function in an
in vitro cellular model, such as its up-regulation during mega-
karyocytic di¡erentiation of K562 cells. Although antisense S-
oligos and PNA have been used successfully in blocking gene
expression of proteins such as GRB2, COX-2, and c-MYC
[17^19], our attempts to down-regulate DAB2 by these ap-
proaches were ine¡ective. Transfection e⁄ciency appears not
to account for the failure because most of the transfected cells
took up the oligonucleotides e⁄ciently. That DAB2 antisense
oligonucleotides proved ine¡ective is most probably due to
targeting sequences that are not appropriate, given that there
are few general rules to guide their design.
The recent development of the RNAi technique in mamma-
lian cells has prompted us to explore the use of siRNA to
moderate DAB2 expression. Of the DAB2 siRNAs tested,
Dab2^419 is incapable of decreasing the levels of DAB2.
The 1 bp mismatch in the dsRNA region of Dab2^419 may
account for its loss in gene-speci¢c silencing of DAB2. Alter-
natively, the targeting sequences of Dab2^419 may not be
appropriate for the function of siRNA. Dab2^2112 is e¡ective
in the inhibition of DAB2 expression, regardless of the ex-
pression in wild type DAB2, EGFP-DAB2, or TPA-mediated
Fig. 2. Modulation of TPA-induced DAB2 expression by DAB2
antisense S-oligos, PNA, and siRNA. A: Expression of DAB2 in
myeloid leukemic cell lines. K562, MEG-01, HL-60, and HEL cells
were plated at a density of 1.5U104/ml. On the following day, cells
were treated with TPA (10 ng/ml) or solvent control ethanol for 48
h. The cell lysates were collected and subjected to Western blot
analysis with the p96 antibody. The increased background of the
HL-60 cells was due to a longer exposure time of the ¢lm. B: Ef-
fects of antisense PNA and S-oligos on TPA-induced DAB2 expres-
sion. Non-transfected K562 cells (control) as well as K562 cells
transfected with the DAB2 antisense PNA (lower panel), sense and
antisense S-oligos (upper panel) were treated with TPA (T) or ve-
hicle control ethanol (E) for 48 h. The cell lysates were collected for
Western blot analysis with the p96 antibody and reprobed with L-
actin for the control of equal loading. C: E¡ects of DAB2 siRNA
on TPA-induced DAB2 expression. K562 cells were transfected with
6 Wg pTOPO-U6 (lanes 1, 4, 7), Dab2^419 (lanes 2, 5, 8), and
Dab2^2112 (lanes 3, 6, 9). At 24 h after transfection, the cell den-
sity was adjusted to 1.5U104/ml and the cells were subjected to
treatment with 2 ng/ml (lanes 4^6) and 10 ng/ml (lanes 7^9) TPA,
or solvent control ethanol (lanes 1^3). At 24 and 48 h after TPA
treatment, cell lysates were collected for Western blot analysis with
the p96 antibody. For control of equal loading, the membranes
were reprobed with the anti-L-actin antibody.
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endogenous DAB2 induction. Most importantly, the inhibi-
tion is DAB2-speci¢c. This notion is supported by the results
showing that Dab2^2112 does not a¡ect the expression of
EGFP, RFP, and membrane protein scramblase. The speci¢c-
ity of Dab2^2112 has been further ensured by searches of the
NCBI database. No sequence similarity was found between
the Dab2^2112 targeting sequences and other known mRNA
sequences. Therefore, these observations reveal that Dab2^
Fig. 3. E¡ects of Dab2^2112 on cellular adhesive function, morphological changes, and integrin L3 expression associated with megakaryocytic
di¡erentiation of K562 cells. A: Dab2^2112 dispersed TPA-induced cell aggregations. K562 cells were transfected with pTOPO-U6 (upper pan-
el) and Dab2^2112 (lower panel) in the presence of LF2000 for 24 h. After adjusting the cell density to 3U104/ml, the cells were treated with
ethanol or TPA for 48 h. The cell adhesive properties were observed with phase contrast microscopy and represented ¢elds are shown (100U).
Higher magni¢cation ¢elds (400U) for TPA-treated cells are also presented for the evaluation of the e¡ect on spreading. The cell aggregates
and cell spreading were quanti¢ed as described in Section 2 and are presented as the relative ratio to the control cells. In the cell aggregation
assay, the numbers of cell aggregates in the 24 h ethanol-treated, pTOPO-U6-transfected control cells were arbitrarily set as 1. In the cell
spreading assay, the numbers of spreading cells in the 24 h TPA-treated, pTOPO-U6-transfected control cells were arbitrarily set as 1. No
spreading cells were observed in the ethanol-treated control cells. The data represented the averageTS.E.M. of two independent experiments
with three assays in each experiment. B: Dab2^2112 had little e¡ect on TPA-induced morphological changes and integrin L3 expression. Ali-
quots of cells from panel A were cytospun, stained with Liu’s stain reagents, and observed by light microscopy. In addition, the lysates for
K562 cells transfected with pTOPO-U6 (lanes 1 and 3) and Dab2^2112 (lanes 2 and 4) were subjected to Western blot analysis with anti-integ-
rin L3 antibody. The expression of L-actin was used for the control of equal protein loading.
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2112 is a speci¢c and functionally active modulator of DAB2
expression.
Megakaryocytic di¡erentiation of K562 cells associates with
changes in morphology, cellular adhesive properties, integrin
L3 expression, and MAPK activation [20]. A recent study has
revealed a role of DAB2 in the adhesion of RAW cells to
laminin and collagen type IV [4]. This has prompted us to
determine whether DAB2 plays any role in the cellular adhe-
sive function of K562. The breakdown of cell aggregation by
Dab2 siRNA suggests that, in addition to the regulation of
cell^extracellular matrix adhesion [4], DAB2 is involved in the
control of cell^cell adhesion when K562 cells undergo di¡er-
entiation. The disruption of TPA-induced cell aggregates is
DAB2-speci¢c, since siRNAs targeting ¢re£y luciferase and
membrane protein scramblase do not a¡ect the formation of
cell aggregates (data not shown). We have noted that,
although DAB2 induction also accompanies megakaryocytic
di¡erentiation of HEL and MEG-01 cells, these two cell types
lack cell^cell adhesion and do not form cell aggregates in our
assay condition. They adhere to the tissue culture dishes
shortly after induction of di¡erentiation. These observations
suggest that induction of DAB2 is necessary but not su⁄cient
to explain the cellular adhesive behavior of a particular cell
type. An additional factor may be involved and act with
DAB2 to control cell^cell adhesion. Alternatively, HEL and
MEG-01 cells may require pathways other than K562 to pro-
duce adhesion. In support of this notion, these cell lines were
shown to have distinct expression patterns for proteins in-
volved in cell adhesion [21,22]. Furthermore, a di¡erential
inhibitory e¡ect of K- and L-tocopherol on cell adhesion of
K562 and HEL cells has been observed [23]. The detailed
molecular mechanisms of DAB2 in regulating cell^cell adhe-
sion are currently under investigation in our laboratory.
The present study also suggests that DAB2 may play a role
in decreasing MAPK activity following sustained MAPK ac-
tivation. This is consistent with reports that have demon-
strated that DAB2 negatively regulates MAPK activity in
several epithelial and macrophage cell lines [1,4]. Since we
have shown that DAB2 is induced in a MAPK-dependent
manner [9], our results further imply the presence of a recip-
rocal regulatory loop between DAB2 and MAPK. This regu-
lation may represent a mechanism, in addition to protein
kinase C down-regulation [24] and MAPK phosphatase acti-
vation [25], to control TPA and MAPK signaling and to
maintain the cellular homeostasis status. In contrast to our
results, a study using retinoic acid-induced F9 embryonic car-
cinoma cells shows that DAB2 does not a¡ect MAPK activity
and uncoupling of MAPK activation and fos suppression [26].
Therefore, the regulation between DAB2 and MAPK appears
to be cell type-speci¢c.
In summary, this study shows for the ¢rst time that a func-
tional DAB2 siRNA is useful in the down-regulation of
DAB2 expression. The results indicate a role of DAB2 in
cell^cell adhesion and have revealed a mutual regulation be-
tween DAB2 and MAPK during K562 cell di¡erentiation.
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